G1 Therapeutics
G1 Therapeutics is an oncology biopharmaceutical company acquired by Pharmacosmos in September 2024. It developed and commercialized COSELA (trilaciclib), a medicine used before certain chemotherapy regimens to reduce chemotherapy-induced bone marrow suppression in adults with extensive-stage small cell lung cancer.
Key facts
| Legal Name | G1 Therapeutics, Inc. |
|---|---|
| Company Operating Status | Acquired |
| Full Address | 700 Park Offices Drive Suite 200 Research Triangle Park, NC 27709 |
| Previous Name | G-Zero Therapeutics, Inc. |
| Stock Symbol | GTHX |
| Ticker Symbol | GTHX |
| Wellfound ID | g1-therapeutics |
Contact details
Email and phone for G1 Therapeutics are available to signed-in members of CliffBio.
Sign in to view